Skip to main content

Table 5 Percent changes in median (mean) antibody levels in sera and corresponding IC during 24-month follow-up

From: Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

 

0–3 months

0–6 months

0–12 months

0–24 months

 

Serum

IC

Serum

IC

Serum

IC

Serum

IC

Antibody

Change

p

Change

p

Change

p

Change

p

Change

p

Change

p

Change

p

Change

p

dsDNA

− 21.4

< 0.001

− 18.2

0.008

− 34.4

< 0.001

− 25.0

0.049

− 32.3

< 0.001

− 40.3

0.044

− 34.9

0.022

− 36.4

0.002

(− 17.2)

n = 41

(− 6.6)

n = 41

(− 27.1)

n = 35

(6.2)

n = 35

(62.7)

n = 30

(1.7)

n = 30

(− 24.8)

n = 22

(− 28.2)

n = 21

Histone

− 23.1

< 0.001

0

0.414

− 26.1

< 0.001

0

0.687

−24.8

0.1051

−17.9

0.595

−23.6

0.411

− 13.9

0.015

(− 17.2)

n = 41

(95.4)

n = 41

(5.5)

n = 35

(15.6)

n = 34

(64.9)

n = 30

(23.3)

n = 29

(4.4)

n = 22

(− 6.5)

n = 21

Ribosomal P

− 20.0

< 0.001

0

0.993

− 31.2

< 0.001

3.33

0.841

− 36.5

< 0.001

− 26.9

0.105

− 41.8

0.001

− 15.9

0.933

(− 13.6)

n = 41

(49.5)

n = 38

(− 32.4)

n = 35

(25.2)

n = 32

(− 28.7)

n = 30

(1.9)

n = 28

(− 30.8)

n = 22

(40.6)

n = 21

PCNA

−26.0

< 0.001

−11.2

0.091

−31.5

< 0.001

2.6

0.773

−30.2

< 0.001

2.2

0.442

−36.1

< 0.001

−31.1

0.006

(− 19.0)

n = 41

(− 3.0)

n = 41

(− 24.6)

n = 35

(22.3)

n = 35

(− 10.3)

n = 30

(15.1)

n = 30

(− 35.6)

n = 22

(− 17.3)

n = 21

SSA/Ro60

− 2.8

0.034

− 1.4

0.222

− 7.1

0.0115

− 7.1

0.599

− 7.0

0.048

− 21.7

0.211

− 6.1

0.0575

− 33.0

0.007

(− 8.6)

n = 41

(1.3)

n = 41

(− 9.3)

n = 35

(30.2)

n = 35

(10.2)

n = 30

(8.1)

n = 30

(28.9)

n = 22

(− 6.5)

n = 21

SSB/La

− 11.9

< 0.001

− 14.3

0.274

− 14.9

0.008

− 7.7

0.053

− 24.9

0.008

− 20.8

0.051

− 27.7

0.041

− 14.2

0.143

(− 11.0)

n = 41

(9.0)

n = 41

(− 13.1)

n = 35

(16.3)

n = 35

(54.2)

n = 30

(9.4)

n = 30

(− 23.7)

n = 22

(23.0)

n = 21

SSA/Ro52

− 9.3

0.1787

− 14.3

0.124

− 6.8

0.474

− 3.5

0.315

− 3.8

0.078

− 15.5

0.292

− 10.6

< 0.001

− 28.2

0.005

(− 6.8)

n = 41

(− 4.7)

n = 41

(− 7.7)

n = 35

(22.7)

n = 35

(− 6.7)

n = 30

(8.9)

n = 30

(− 20.4)

n = 22

(− 11.8)

n = 21

Sm

− 25.0

< 0.001

0

0.406

− 16.7

0.005

0

0.813

− 12.8

0.228

− 27.3

0.292

− 30.0

0.0532

− 40.9

0.050

(− 24.6)

n = 41

(0.1)

n = 33

(− 18.0)

n = 35

(2.0)

n = 31

(17.7)

n = 30

(− 12.0)

n = 28

(− 1.5)

n = 22

(− 26.6)

n = 18

U1RNP

− 13.8

0.0001

− 12.5

0.111

− 13.3

0.010

− 16.7

0.167

− 12.3

0.006

− 26.6

0.001

− 22.8

< 0.001

− 26.3

< 0.001

(− 4.4)

n = 41

(4.4)

n = 41

(3.4)

n = 35

(2.2)

n = 35

(17.5)

n = 30

(3.8)

n = 30

(− 19.3)

n = 22

(− 24.4)

n = 21

Sm-U1RNP

− 14.7

< 0.001

0

0.621

− 15.2

< 0.001

− 14.3

0.137

− 22.4

0.009

− 33.2

0.019

− 31.5

< 0.001

− 25.0

0.007

(− 17.4)

n = 41

(7.4)

n = 40

(− 15.7)

n = 35

(0.8)

n = 34

(11.1)

n = 30

(4.9)

n = 30

(− 25.5)

n = 22

(− 9.2)

n = 21

  1. Differences were compared pairwise with the Wilcoxon signed rank test. Negative values indicate decreasing antibody levels; significant changes are presented in italics. The number of SLE-samples in the individual pairwise comparisons is stated below the p values